Skip to main content

Table 3 Patient, cancer, and chemotherapy characteristics

From: Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases

  All patients (n=357) Gold standard (n=82) FN Patients: neutropenia, primary position (n=54) FN Patients: neutropenia, any position (n=71) FN Patients: Neutropenia + Fever,Any Position (n=28) FN Patients: neutropenia or fever, any position (n=78) FN Patients: neutropenia, fever, or infection, any position (n=201)
Patient   
 Age (years), mean±SD 64.2±13.0 62.1±13.8 63.3±15.1 62.6±14.8 61.3±16.3 63.0±14.5 65.5±12.3
 Male, % 56.0 51.2 42.6 40.9 39.3 44.9 56.2
 Body Mass Index (kg/m2), mean±SD 27.3±5.9 27.8±4.5 27.8±4.7 28.1±4.7 28.1±5.7 28.2±5.1 27.3±5.2
 N 332 77 51 67 28 74 192
 Absolute Neutrophil Count  (cells/L), mean±SD 4.4±5.6 0.2±0.3 0.3±0.9 0.9±3.3 0.2±0.2 1.1±3.5 4.4±6.3
 N 357 82 54 71 28 78 201
Cancer        
 Type %        
  Bone, Connective Tissue, Skin, Breast
   Female Breast 9.8 19.5 18.5 18.3 28.6 17.9 11.9
   Other 2.8 1.2 1.9 2.8 3.6 2.6 2.5
  Respiratory and Intrathoracic Organs
   Trachea, Bronchus, Lung 19.3 17.1 9.3 9.9 14.3 10.3 20.9
   Other 1.4 2.4 5.6 4.2 3.6 3.8 2.0
  Digestive Organs and Peritoneum
   Colon/Rectum 10.9 9.8 5.6 5.6 7.1 5.1 9.5
   Pancreas 7.8 1.2 1.9 2.8 0.0 5.1 7.0
   Esophagus 2.5 2.4 0.0 0.0 0.0 0.0 1.0
   Other 3.1 0.0 0.0 0.0 0.0 0.0 2.0
  Non-Hodgkin's Lymphoma 11.2 20.7 25.9 23.9 28.6 24.4 14.9
  Genitourinary Organs
   Bladder 4.2 3.7 3.7 4.2 0.0 3.8 5.0
   Ovarian 3.6 1.2 5.6 4.2 0.0 3.8 3.0
   Prostate 2.8 0.0 0.0 0.0 0.0 0.0 3.0
   Uterus 1.7 0.0 0.0 1.4 0.0 1.3 0.5
   Other 2.8 1.2 1.9 1.4 0.0 1.3 2.0
  Lip, Oral Cavity, and Pharnyx 2.0 1.2 0.0 0.0 0.0 0.0 1.5
  Blood Cancers 6.7 13.4 13.0 14.1 14.3 14.1 8.0
  Hodgkin’s Lymphoma 1.7 1.2 1.9 1.4 0.0 1.3 0.5
  Other 5.6 3.7 5.6 5.6 0.0 5.1 5.0
 Presence of Metastases, % 35.0 24.4 22.2 21.1 17.9 20.5 26.4
Chemotherapy
 No. of Myelosuppressive Drugs in Cycle 1, %
  1 32.2 20.6 26.1 27.4 38.1 29.4 29.2
  2 47.2 50.7 45.7 46.8 38.1 44.1 49.7
  ≥3 20.6 28.8 28.3 25.8 23.8 26.5 21.1
 Year of Initiation, %        
  2004-2005 41.7 37.8 42.6 42.3 14.3 39.7 37.3
  2006-2007 28.3 28.1 22.2 23.9 32.1 23.1 31.4
  2008-2010 30.0 34.2 35.2 33.8 53.6 37.2 31.3